Stifel Downgrades HilleVax to Hold After HIL-214 Norovirus Vaccine Candidate Discontinuation
Tuesday, 9 July 2024, 16:52
Stifel Downgrades HilleVax to Hold
Stifel has lowered its rating on HilleVax (HLVX) to hold after the company's announcement of discontinuing the development of its norovirus vaccine candidate HIL-214 for infants.
Study Failure and Price Target
- Impact on Stock Rating: Downgraded to hold
- Price Target Adjustment: Reduced to $3
- Reason: Discontinuation of HIL-214
This decision reflects the concerns surrounding the failed study and its repercussions on HilleVax's future prospects in the pharmaceutical industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.